Therefore, inhibitors against the kinase P-TEFb (CDK9/CyclinT1) [17], the histone methyltransferases DOT1L [18], and the bromodomain and extra-terminal domain (BET) family of proteins [19] are currently in clinical testing for AML. This evidence concerns the gene CDK9 and acute myeloid leukemia.